Fig. 1

The expression of SUV39H2 is upregulated in patients with OS in association with reduced survival rate. a SUV39H2 expression in OS and normal samples from the TCGA database detected through UALCAN website. b Kaplan–Meier survival curves showing the effect of SUV39H2 expression on OS patient survival from the TCGA database. c SUV39H2 mRNA expression in OS tissues and paracancerous tissues tested using RT-qPCR. d SUV39H2 protein expression normalized to GAPDH in OS tissues and paracancerous tissues tested using Western blot analysis. *p < 0.05 vs. paracancerous tissues. e SUV39H2 expression in hFOB1.19, U2OS, HOS and MG63 cells assessed by RT-qPCR. *p < 0.05 vs. hFOB1.19 cells. f The relationship between SUV39H2 expression and the overall survival rate of patients with OS (n = 58) analyzed using Kaplan-Meier survival analysis. Measurement data were expressed as mean ± standard deviation derived from at least 3 independent experiments. Paired t-test was used for comparison between the data of carcinoma and its paracancerous tissues. One-way ANOVA was applied for comparisons among data of hFOB1.19, U2OS, HOS and MG63 cells. Kaplan-Meier graphical analysis was used to calculate the survival rate of patients (n = 58)